The basic patent for imatinib, the main ingredient in Gleevec, expired in Canada on April 1, 2013. In the U.S. the patent continues until 2015. There has also been some recent news about generic imatinib being "approved for marketing" by the European Medicines Agency.
There appears to be one company now selling "generic imatinib" in Canada (note that the names "Gleevec" and "Glivec" belong to Novartis): Apotex Inc. (HQ in Toronto, Canada). Here is the Apotex flyer:
Teva Pharmaceuticals (an Israeli company) has previously expressed interest in selling imatinib in Canada, but I did not see it listed on their website.
The Teva generic imatinib was "tested" (limited to bioequivalence testing) in Europe and has been approved by the European Medicines Agency, but I am not aware if sales will be allowed in Europe prior to U.S. patent expiration: